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Abstract
Background: Refractory cytopenia with multilineage dysplasia (RCMD) is a subgroup of myelodysplastic syndrome
(MDS), which belongs to oncohematological diseases, occurring particularly in elderly patients, and represents a
heterogeneous group of bone marrow diseases. The goal of this study was to look for plasma proteins that
changed quantitatively or qualitatively in RCMD patients.
Results: A total of 46 plasma samples were depleted, proteins were separated by 2D SDS-PAGE (pI 4-7), and
proteomes were compared using Progenesis SameSpots statistical software. Proteins were identified by nanoLC-
MS/MS. Sixty-one unique, significantly (p < 0.05, ANOVA) different spots were found; proteins in 59 spots were
successfully identified and corresponded to 57 different proteins. Protein fragmentation was observed in several
proteins: complement C4-A, complement C4-B, inter-alpha-trypsin inhibitor heavy chain H4, and endorepellin.
Conclusions: This study describes proteins, which change quantitatively or qualitatively in RCMD patients, and
represents the first report on significant alterations in C4-A and C4-B complement proteins and ITIH4 fragments in
patients with MDS-RCMD.
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Background
Refractory cytopenia with multilineage dysplasia (RCMD)
is a subgroup of myelodysplastic syndrome (MDS). MDS
itself belongs to the group of oncohematological diseases,
occurring particularly in elderly patients. It represents a
heterogeneous group of bone marrow diseases character-
ized by blood cytopenias, ineffective hematopoiesis, and
dysplasia in one or more blood cell lines. According to
the WHO (World Health Organization) classification of
MDS, RCMD is defined by the presence of bicytopenia or
pancytopenia in peripheral blood and dysplastic changes
that are present in 10% or more of the cells in two or
more myeloid lineages in the bone marrow (with less
than 15% ringed sideroblasts) [1].
Despite the efforts and development in MDS research
within the last several years, the pathogenesis of MDS
remains still unclear. Several studies have shown an up-
or down-regulation of different groups of genes in MDS
patients [2-6]; however, the results are in some cases
controversial and difficult to interpret. Proteomic tech-
niques might provide a new and more detailed set of
information clarifying the molecular mechanisms
involved in the development of MDS [7]. Complex pro-
tein-protein networks reflect the changes at the tran-
scription level, as well as changes induced by protein
modifications depending on (patho) physiological condi-
tions in organisms. Posttranslational modifications of
proteins including fragmentation or cross-linking are
examples of changes detected exclusively by proteomic
techniques [8], which may play a crucial role in the
development and progression of the disease [9,10].
Two-dimensional gel electrophoresis (especially 2D
SDS-PAGE) is one of the most widespread proteomic
techniques. Despite some disadvantages like the co-iden-
tification of proteins within a protein feature, a limited
range of detection of low-abundant proteins, or pro-
blems with the analysis of basic and low molecular
weight proteins, 2D electrophoresis offers both the pos-
sibilities to search for protein level changes and for pro-
tein posttranslational modifications. Differential
proteome pattern analysis, based on either quantitative
or qualitative changes, combined with the identification
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insight into the changing proteomes.
The aim of this study was to identify both quantitative
and qualitative changes in plasma proteomes of MDS
patients with RCMD using 2D electrophoresis.
Methods
A total of 22 RCMD patient (11 males and 11 females)
plasma samples and 24 healthy controls (10 males and
14 females) have been investigated. The diagnosis of
RCMD was established according to the WHO classifi-
cation criteria [1]. The age of the patients ranged from
21 to 72 years. Healthy control ages ranged from 20 to
36 years. All individuals tested agreed to participate in
the study on the basis of an informed consent. All sam-
ples were obtained and analyzed in accordance with the
Ethical Committee regulations of the Institute of Hema-
tology and Blood Transfusion.
Blood samples were collected by venipuncture into
tubes coated with EDTA. Plasma was obtained by the
centrifugation (5 min, 4000 × g) of blood samples; and
plasma aliquots were then transferred to polypropylene
Eppendorf tubes and stored at -70°C until used. Thawed
plasma samples were centrifuged (5 min, 12000 × g),
diluted 1:3 by depletion buffer (Agilent, Santa Clara,
CA, USA) and filtrated using 0.22 μm Spin filters (Agi-
lent,) for 1 minute by centrifugation at 12000 × g. A
MARS Hu-14 4,6 × 100 mm column (Agilent) was used
to deplete fourteen high-abundant proteins (albumin,
IgG, antitrypsin, IgA, transferrin, haptoglobin, fibrino-
gen, alpha-2-macroglobulin, alpha-1-acid glycoprotein,
IgM, apolipoprotein AI, apolipoprotein AII, complement
C3 and transthyretin). 5K MWCO Spin Concentrators
(Agilent) were used to desalinate and concentrate the
samples (3000 × g, 20°C). MilliQ water (4 mL) was
added to concentrated samples and the desalinating-
concentrating step was repeated three times. Finally,
desalinated and concentrated samples were vacuum
dried, frozen rapidly, and stored at -70°C.
1D and 2D SDS-PAGE, image analysis, protein diges-
tion, and mass spectrometry analysis were performed as
described previously [8,11,12]. Briefly, isoelectric focus-
ing (IPG strips pI 4-7, 7.7 cm) and SDS-PAGE (8 × 10
cm, 10% resolving gel, 3.75% stacking gel, 5°C, 30 mA/
gel) were used in the first and the second dimensions,
respectively. Gels were stained with colloidal Coomassie
blue, scanned, and processed with Progenesis Same-
Spots software (Nonlinear Dynamics, Newcastle upon
Tyne, UK), which computed multiplication (fold) and p-
values of all spots using one-way ANOVA analysis.
PCA (Principal Component Analysis) was performed to
assess whether grouping of patients and healthy controls
based on proteomic methods reflects their stratification
using classical clinical diagnosis. PCA was performed
making use of the same software focusing only on the
spots of statistical significance employed for protein
identification.
Selected spots were excised from the gel, and proteins
were in-gel digested by trypsin. An HCT ultra ion-trap
mass spectrometer (Bruker Daltonics, Bremen, Ger-
many) with nanoelectrospray ionization, coupled to a
UltiMate 3000 nanoLC system (Dionex, Sunnyvale, CA,
USA) was used for mass spectrometry analysis. Proteins
were identified using tandem mass spectrometry. Mascot
(Matrix Science, London, UK) was used for database
searching (SWISS-PROT release 2010_12). Two unique
peptides (fulfilling a minimal Mascot score) were neces-
sary to successfully identify a protein. Two cleaning
runs were performed before and after each sample run
to eliminate peptide carry-over between nanoLC separa-
tions. The N-terminal tryptic peptide of the endorepellin
LG3 fragment corresponding to
4197DAPGQY-
GAYFHDDGFLAFPGHVFSR
4221 was monitored (z =
+2, precursor ion 1387.0 m/z, selection window width =
2) as described in previous literature [13].
Western blotting was performed as described pre-
viously [8]. Proteins were transferred from gel to a
PVDF membrane (10 V constant voltage for 1 hr); the
membrane was then incubated with a blocking buffer
(3% BSA in PBS) at 4°C overnight, rinsed; and incubated
with primary antibodies: anti-ITIH4 (Abnova, Taipei,
Taiwan), 1:2000 dilution, at 30°C for 45 min, or anti-
HSPG2 (LifeSpan BioScience, Seattle, WA, USA), 1:1000
dilution, at 30°C for 45 min. Then the membrane was
incubated with the secondary antibody, rabbit anti-
mouse IgG antibody conjugated with peroxidase (Sigma-
Aldrich, Prague, Czech Republic), 1:60000 dilution, at
30°C for 45 min. After rinsing, a chemiluminescent sub-
strate (SuperSignal West Pico; Thermo Scientific, Wal-
tham, MA, USA) was added to the membrane for 5
min; and an appropriate film exposition (Amersham
Hyperfilm ECL; GE Life Sciences, Piscataway, NJ, US)
was performed.
Complement C4a des Arg plasma level was measured
using a commercial EIA kit (Enzo Life Sciences, Farm-
ingdale, NY, USA). Samples were measured in duplicate
according to manufacturer instructions. Results were
expressed as means ± standard deviations. An unpaired
t-test was used for comparison of complement C4a des
Arg plasma levels when the RCMD group was compared
with the control group.
Results
2D gels were prepared for the experiment, and scanned
2D gel images were divided into RCMD (n = 22) and
the control group (n = 24). Comparing these two groups
we found 61 unique spots that differed significantly (p <
0.05) in normalized volumes (Figure 1). Proteins in 59
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57 different proteins. The list of all spots including
ANOVA p-values, the multiplication (fold value), pro-
tein identification with the number of identified peptides
(unique peptides above the threshold score), protein
accession number (Swiss-Prot), the sequence coverage,
both calculated (theoretical) and experimental values of
pI and molecular weight, is summarized in Table S1
(See additional file 1: Table S1).
Protein fragmentation was observed in several pro-
teins, when comparing protein molecular weights esti-
mated on 2D maps with known or predicted values
(complement C4-A, complement C4-B, inter-alpha-tryp-
sin inhibitor heavy chain H4, endorepellin). Combining
the 2D electrophoresis data with mass spectrometry
results, several fragments were identified. Both comple-
ment C4-A and C4-B were identified in 17 spots with
molecular weights ranging from around 20 to 100 kDa.
Sequences of the identified peptides corresponded to
the complement C4-A(B) fragments, as well as their
molecular weights: complement C4 beta chain, comple-
ment C4-A alpha chain, complement C4-B alpha chain,
complement C4 gamma chain, C4b-A, C4b-B, C4d-B,
a n dC 4 c .M o s to ft h es p o t sw i t hi d e n t i f i e dc o m p l e m e n t
C4-A(B) had their normalized volumes increased in
RCMD, when compared to the control group. Although
co-identification of other proteins within a spot con-
fused interpretation of the results, there were several
spots (12, 15, 24, and 33) with unique identification of
fragments; these spots corresponded to the C4c
Figure 1 Positions of significantly differed spots on a 2D gel. Positions of all spots that were found to significantly differ in 2D gels of
RCMD patients and healthy controls when mutually compared. The 2D gel of a patient sample was used as an illustrative gel to display spot
positions.
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24 and 33). Normalized volumes of all of these spots
were increased in RCMD (1.9 and 1.8 fold for C4c, 1.7
and 1.5 fold for C4 gamma); and thus showed that com-
plement C4-A(B) fragmentation or fragment modifica-
tions were present in RCMD patients at a higher rate.
An inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4)
was identified in 13 spots, with estimated molecular
weights of about 35 and 100 kDa (except spot 48).
These molecular weights corresponded to 35 kDa ITIH4
fragments, and to an uncleaved ITIH4 (120 kDa). The
estimated molecular weight of spot 48 was about 80
kDa and probably corresponded to 70 kDa ITIH4 frag-
ment, however, this band was not observed when wes-
tern blot analysis was performed. Sequences of peptides
identified by MS/MS corresponded to these polypep-
tides, in agreement with the electrophoresis data. In
spite of the co-identification of other proteins within the
spots with an identified ITIH4, there was an obvious
trend in the changes between RCMD and the control
group. All spots with ITIH4 fragments (spots 41, 45, 46,
48, 49, 52, 55, and 58) had the normalized volumes
decreased in RCMD, while normalized volumes of spots
with unprocessed (uncleaved) ITIH4 were increased in
RCMD, when compared with the control group. Identi-
fication of ITIH4 (ucleaved protein containing spots 43,
50, 53, 60, and 61) was validated by 2D SDS-PAGE wes-
tern blotting (Figure 2). ITIH4 expression was assessed
by western blot analysis: a single band of more than 100
kDa molecular weight was observed and corresponded
to the uncleaved ITIH4. No difference in ITIH4 expres-
sion between the patient group (n = 8) and the control
group (n = 8) was observed (Figure 2). Using monoclo-
nal anti-ITIH4 antibody capable of detecting uncleaved
ITIH4 and 70 kDa ITIH4 fragment we did not observe
t h e7 0k D aI T I H 4f r a g m e n t( t h ea n t i b o d yw a sn o t
Figure 2 ITIH4 western blot analysis. (A) A segment of 2D SDS-PAGE gel containing spots with uncleaved ITIH4 (spots 43, 50, 53, 60, and 61)
and (B) 2D western blot analysis (ITIH4) - a segment corresponding to the highlighted area on the 2D gel; (C) illustrations of 1D western blot
analysis of ITIH4 and its bands in both the control and RCMD groups corresponding to the molecular weight of 2D western blot (and 2D SDS-
PAGE) ITIH4 spots are shown.
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brane-specific heparan sulfate proteoglycan core protein
(spot 34), known as perlecan, fragmentation was
observed in RCMD with a difference of 1.5 fold, when
compared with the control group. All identified peptide
sequences corresponded to the perlecan fragment
endorepellin (3687-4391 amino acid sequence of perle-
can) or more precisely to the perlecan/endorepellin frag-
ment LG3 (4197-4391 amino acid sequence of perlecan).
The sequences of three peptides fulfilling a minimal
Mascot score for identity were as follows:
4236TSTASGLLLWQGVEVGEAGQGK
4257,
4258DFISLGLQDGHLVFR
4272,a n d
4330GSVYIGGAPD-
VATLTGGR
4347 (See additional file 2: Figure S1). One
additional peptide fulfilled a minimal Mascot score for
homology:
4222SLPEVPETIELEVR
4235.T h ef r a g m e n t a -
tion of perlecan was further monitored by western blot-
ting (n = 8, each group) but no bands or spots (using
1D or 2D western blot) corresponding to the position
(or Mw) of the spot 34 were observed.
PCA was performed to assess whether grouping of
patients and healthy controls based on proteomic meth-
ods reflects their stratification using classical clinical
diagnosis. Analysis was based on spots that significantly
differ according the mentioned statistical criteria (p <
0.05, ANOVA). PCA showed an obvious separation of
all samples (aligned gel images) into two aggregates that
corresponded to the RCMD and the control group,
respectively (Figure 3).
The plasma level of complement C4a des Arg was
measured in both control and patient groups: 5.8 ± 3.1
μg/mL (the control group, n = 19) and 6.4 ± 9.6 μg/mL
(the RCMD group, n = 19). No significant difference
was observed between these two groups (t-test, p =
0.83).
Discussion
In this study we present data characterizing changes in
t h ep l a s m ap r o t e o m eo fp a t i e n t sw i t hR C M D .M o s to f
the identified changes are related to the complement
C4-A and C4-B proteins and to the fragmentation of
several plasma proteins. Among all the identified pro-
teins, albumin was observed in the largest number of
spots (26 spots in total). Although the immunodepletion
column was used to deplete high-abundant plasma pro-
teins, several of them were identified or co-identified
within many spots (albumin, haptoglobin, fibrinogen,
apolipoprotein AI and complement C3). This is prob-
ably a result of posttranslational modifications or frag-
mentation of these proteins, which might have affected
the process of immunodepletion by influencing the
binding of the proteins to stationary phase of the deple-
tion column. In the case of albumin, there was always a
decrease in the spot normalized volume in RCMD when
this protein was identified uniquely within a spot (2, 7,
17, 20 etc.). This suggests that the albumin modification
was not caused by RCMD (it was present in healthy
control plasma samples), the decrease in the spot
volume might be caused by acute phase reaction. The
other four high-abundant plasma proteins were not
uniquely identified within their spots. At present it is
hard to speculate about the possible impact of this
finding.
Our study demonstrates alterations in C4-A and C4-B
complement proteins. The fragmentation, or modifica-
tion of C4 fragments of both proteins was observed with
an approximately 2 fold (C4c fragment) and 1.6 fold (C4
gamma) increase in the RCMD group, when compared
to the healthy controls. C4c and C4 gamma were the
only C4 (or any other complement) protein fragments
uniquely identified within a spot. Moreover, we detected
all possible fragments of C4-A(B) produced by proces-
sing of their precursors (described in Results)a sn o n -
unique identifications. The plasma level of complement
C4a des Arg was measured in both control and patient
groups. There was higher variability of concentration
values in RCMD patients when compared to the control
group but no statistically significant difference in the
plasma level between the two groups was observed. In
view of the fact that the results obtained by electrophor-
esis showed two-fold increase of normalized spot
volumes in the RCMD group with low variability (p-
values of spots 8, 12 or 15 less than 0.001) we suppose
t h a tt h eo b s e r v e dc h a n g e sw e r en o ta s s o c i a t e dw i t h
complement activation. This assumption is also sup-
ported by the fact that no changes in other complement
proteins were observed. Our result may be explained by
Figure 3 Principal Component Analysis.P C Aw a sp e r f o r m e dt o
assess whether grouping of patients and healthy controls based on
proteomic methods reflects their stratification using classical clinical
diagnosis. Analysis was based on spots that significantly differ
according the mentioned statistical criteria (p < 0.05, ANOVA).
Principal Component Analysis (PCA) showed the separation of all
samples into two aggregates that corresponded to the RCMD (blue
dots) and the control group (pink dots).
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cause of fragmentation in RCMD patients [10]. The
immune system plays substantial and diverse roles in
the development of cancer; it may either eliminate the
initiation of cancer development or facilitate cancer pro-
gression [14,15]. The complement system, as a part of
the immune system, participates in immune response;
with it having been shown recently that the C4d frag-
ment may be of clinical interest in the case of transplan-
tations and consequential rejections [16-18]. Although
the most expected cause of complement activation
would be infection, it has been recently shown that
complement activation products are also involved in
promoting tumor growth [14,19]. Experimental studies
have shown that tumor growth was greatly reduced in
mice deficient in the complement protein C4 [14]. It is
also known that MDS patients frequently exhibit multi-
ple abnormalities in the expression of neutrophil com-
plement receptors and granular components (>3), as
well as in other cell functions, suggesting the possibility
of using these phenotypic abnormalities in the monitor-
ing of disease progression [20].
Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4)
is involved in acute phase reaction and has been found
to be a possible cancer marker [21]. ITIH4 fragments
have been found to be potentially associated with MDS
[9]; and several authors have shown differences in the
fragmentation of ITIH4 [21,22]. Furthermore, an alter-
nation in ITIH4 fragments has been described in several
malignant diseases [22-25]. In our experiments, we were
able to divide all spots containing ITIH4 into two
groups according to their molecular weight (described
in Results), which corresponded to ITIH4 fragments
(probably produced by kallikrein) and to the uncleaved
protein. In spite of co-identification of other proteins in
spots containing ITIH4, a trend has been observed in
our MDS patients: normalized volumes of all spots that
contained uncleaved ITIH4 were increased in the
RCMD group; while normalized volumes of all spots
with fragmented ITIH4 were decreased in RCMD
patients. Such a difference could be explained by further
ITIH4 fragmentation producing smaller fragments and
peptides, which could not be detected by 2D SDS-
PAGE as designed in our study, or a reduced fragmen-
tation rate of uncleaved ITIH4 in MDS patients. To
assess whether the observed changes could be caused
by changed ITIH4 expression (possible influence of the
acute phase reaction), western blot analysis of ITIH4
was performed. We observed no differences between
the RCMD and control groups, therefore the increase in
spot normalized volumes of uncleaved ITIH4 (as men-
tioned above) was evidently caused by proteins co-iden-
tified within the same spot(s). As the ITIH4 expression
was not changed, the alteration of its fragments could
be caused by a different fragmentation (further proces-
sing of the fragments) as it was suggested in the litera-
ture [23,24]. It is also possible that the fragmentation
level was not changed and the differences observed in
the ITIH4 fragment spots were caused by posttransla-
tional modification(s) or by combination of both the
factors.
Basement membrane-specific heparan sulfate proteo-
glycan core protein, also known as perlecan, is an inte-
gral component of basement membranes. This protein,
identified in spot 34, is cleaved and produces endorepel-
lin, which has anti-tumor and anti-angiogenic properties
[26]. Perlecan (or endorepellin) can be further processed
by bone morphogenic protein-1 (BMP-1) to produce
LG3 peptide, which also has anti-angiogenic properties
[13,27,28]. All peptides identified in spot 34 belonged
not only to perlecan or to its fragment endorepellin, but
all peptide sequences corresponded to LG3 peptide. As
BMP-1 cleaves endorepellin specifically between
4196Asn and 4197Asp [28], trypsin digest of LG3 pro-
duces the N-terminal tryptic peptide (
4197DAPGQY-
GAYFHDDGFLAFPGHVFSR
4221)c o n t a i n i n gt h eN -
terminal non-tryptic site. Identification of this peptide in
the sample could prove whether it is LG3 peptide pro-
duced by the specific proteolytic cleavage of endorepel-
lin by BMP-1, or just an endorepellin fragment
corresponding to the LG3 sequence. As this N-terminal
LG3 peptide was not identified we cannot exclude any
possibility. The normalized volume of spot 34 contain-
ing the LG3 peptide or its fragment was increased in
RCMD by 50%. Alterations of the LG3 peptide were
observed in the plasma of breast cancer patients
(decreased level) [13], in amniotic fluid of pregnant
women with premature rupture of the fetal membrane
[29], or in the urine of end-stage renal failure patients
[30]. The alteration of an endorepellin fragment in
RCMD, whether it is due to a plasma level increase or
posttranslational modification, may be connected to its
anti-tumor and anti-angiogenic properties. This may be
supported by the fact that endorepellin has been shown
to inhibit tumor growth and cancer cell metabolism in
vivo and has been proposed to be a possible anti-tumor
agent [26]. To assess the fragmentation of endorepellin
or the influence of the protein (or further protein frag-
ments) plasma level changes to 2D SDS-PAGE based
results western blot analysis was performed. However,
we did not observe bands or spots (using 1D or 2D wes-
tern blot) corresponding to the endorepellin fragment
(spot 34). The change of spot 34 normalized volume
could be also caused by the presence of other protein(s)
but there was no other co-identified protein except per-
lecan in spite of repeated MS/MS analysis. Nevertheless,
especially proteins of lower Mw (or some glycoproteins
etc.) might cause difficulty in identification so we cannot
Májek et al. Proteome Science 2011, 9:64
http://www.proteomesci.com/content/9/1/64
Page 6 of 8exclude the possibility of co-localized protein(s) within
the spot 34.
An important issue that should be discussed is the
choice of the control group used. As MDS usually
occurs in elderly patients the optimal control group
should match for age as well as for sex. However,
matching the control group for age may be connected
with some difficulties. It is a good assumption that there
may occur some proteome changes related to ageing. A
paper by Ignjatovic et al. [31] points at plasma proteome
differences when compared neonates, children and
adults. Consequently, we suppose that there are some
differences between our RCMD patient group and the
control group because of different age ranges. However,
collecting a control group of healthy individuals of older
age is a problem as there are some conditions that have
to be fulfilled. The main issue is to find healthy indivi-
duals of older age, who do not suffer from other dis-
eases (blood pressure, diabetes etc.). In spite of
collecting such samples, we suppose it will be necessary
to use more control samples of such group to suppress
possible biological variations. Considering that, we
decided to compare our patient group with a “really”
healthy control group as used in the manuscript. As it is
the first proteomic study of RCMD patients we wanted
to see all the changes that would occur. Moreover, there
is a couple of MDS patients of young age (in case of
RCMD from 21 years) that should be compared too.
Nevertheless, it is the future task to compare other con-
trol groups with MDS. Much more difficult task will be
to assess the influence of ageing in “healthy” population
on the plasma proteome.
Conclusions
In conclusion, this study represents the first report on
the significant alterations in C4-A and C4-B comple-
ment proteins and in ITIH4 fragments in patients with
MDS-RCMD. Our results show the involvement of com-
plement system proteins and protein fragmentation in
most of the proteome changes identified in this study.
However, a more extensive study will be needed to com-
pare the results obtained from RCMD patients with
patients from other MDS subgroups. These studies
hopefully should help us to establish a possible role of
the altered activation (modification) of several parts of
complement, the different fragmentation of ITIH4 and
the endorepellin fragment in the promotion of the
pathological clone in MDS.
Additional material
Additional file 1: Table S1. List of spots that significantly differ when
RCMD patients and healthy controls compared.
Additional file 2: Figure S1 - The peptide sequences corresponding
to the perlecan fragment endorepellin. An illustration of the coverage
of perlecan sequence (shown in bold red) that corresponds to the
perlecan fragment endorepellin (3687-4391 amino acid sequence of
perlecan) or more precisely to the perlecan/endorepellin fragment LG3
(4197-4391 amino acid sequence of perlecan). The MS/MS spectra of
three peptides fulfilling a minimal Mascot score for identity
4236TSTASGLLLWQGVEVGEAGQGK
4257,
4258DFISLGLQDGHLVFR
4272, and
4330GSVYIGGAPDVATLTGGR
4347 are shown.
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